SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

[1]  S. Nimer,et al.  Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients , 2010, Bone Marrow Transplantation.

[2]  L. Gil,et al.  Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia. , 2009, Transplantation proceedings.

[3]  C. Wallington-Beddoe,et al.  Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[5]  J. Klein,et al.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. , 2009, Blood.

[6]  P. Böttcher,et al.  Partial lateral corpectomy for ventral extradural thoracic spinal cord compression in a cat , 2008, Journal of feline medicine and surgery.

[7]  A. Dispenzieri,et al.  Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL) , 2007, Bone Marrow Transplantation.

[8]  P. Nathan,et al.  Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection , 2007, Annals of Internal Medicine.

[9]  Stefan Fruehauf,et al.  Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2007, European journal of haematology.

[10]  I. Bruns,et al.  Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. , 2006, Experimental hematology.

[11]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Bruns,et al.  Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2006, Bone Marrow Transplantation.

[13]  E. Jantunen,et al.  High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol , 2006, Bone Marrow Transplantation.

[14]  J. White,et al.  Cutaneous manifestations of granulocyte colony‐stimulating factor , 2006, Clinical and experimental dermatology.

[15]  É. Azoulay,et al.  Respiratory status deterioration during G-CSF-induced neutropenia recovery , 2005, Bone Marrow Transplantation.

[16]  S. Fernandez,et al.  Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome , 2004, Bone Marrow Transplantation.

[17]  Jinny Park,et al.  Correlation of hematopoietic progenitor cell count determined by the SE‐9000™ automated hematology analyzer with CD34+ cell count by flow cytometry in leukapheresis products , 2001, American journal of hematology.

[18]  F. Hernández-Navarro,et al.  Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? , 1999, Blood.

[19]  E. Ito,et al.  Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. , 1998, Blood.

[20]  H. Messner.  Human hematopoietic progenitor in bone marrow and peripheral blood , 1998, Stem cells.

[21]  I. Bertoncello,et al.  Peripheral blood CD34+ cell count reliably predicts autograft yield , 1998, Bone Marrow Transplantation.

[22]  B. Barlogie,et al.  Long-term follow-up after high-dose therapy for high-risk multiple myeloma , 1998, Bone Marrow Transplantation.

[23]  R. Marcus,et al.  Recombinant human granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double‐blind, placebo‐controlled trial , 1992, British journal of haematology.

[24]  B. Coiffier,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. , 1992, Blood.

[25]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[26]  J. Winters,et al.  Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator , 2004, Journal of clinical apheresis.

[27]  J. Fielden,et al.  Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). , 2003, The hematology journal : the official journal of the European Haematology Association.